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Tendon injury is common and debilitating, and it is associated with long-term pain and ineffective healing. It is
estimated to afflict 25% of the adult population and is often a career-ending disease in athletes and racehorses.
Tendon injury is associated with high morbidity, pain, and long-term suffering for the patient. Due to the low
cellularity and vascularity of tendon tissue, once damage has occurred, the repair process is slow and inefficient,
resulting in mechanically, structurally, and functionally inferior tissue. Current treatment options focus on pain
management, often being palliative and temporary and ending in reduced function. Most treatments available do
not address the underlying cause of the disease and, as such, are often ineffective with variable results. The need
for an advanced therapeutic that addresses the underlying pathology is evident. Tissue engineering and re-
generative medicine is an emerging field that is aimed at stimulating the body’s own repair system to produce
de novo tissue through the use of factors such as cells, proteins, and genes that are delivered by a biomaterial
scaffold. Successful tissue engineering strategies for tendon regeneration should be built on a foundation of
understanding of the molecular and cellular composition of healthy compared with damaged tendon, and the
inherent differences seen in the tissue after disease. This article presents a comprehensive clinical, biological,
and biomaterials insight into tendon tissue engineering and regeneration toward more advanced therapeutics.
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Introduction
W ithin the field of orthopedic surgery, damage totendons is the most common soft tissue injury.1
Worldwide, of the 30 million musculoskeletal injuries re-
ported, more than half are believed to involve tendons and
ligaments.2,3 Tendon injuries predominantly affect the el-
derly population, and those involved with high mechanical
load and weight-bearing activities such as athletes. It is
believed that as many as 50% of sports-related injuries in-
volve tendons.4 The prevalence of such injuries is only set to
rise with the increase in average life expectancy and the
popularity of high mechanical load activities such as gym-
nasium use, football, and athletics.5 Tendons are tough
bands of fibrous, viscoelastic, connective tissue that anchor
every muscle of the body to the bone, and they are re-
sponsible for resisting tension and aiding movement.6 It is
critical that tendons have the ability to withstand large
tensile forces exerted on them and are able to provide an
efficient buffering system, absorbing shock and preventing
muscular damage.7 However, this function also makes them
susceptible to damage, microtrauma, and rupture. Tendons
are able to withstand such forces by modifying their struc-
ture after stimulus via a process known as mechanical ad-
aptation.8 At rest, a highly organized crimped configuration
can be seen in the tissue that is conducive to the resistive
capability of tendons.7 When under tensile strain, the
crimped formation is one mechanism that enables the tissue
to distend, absorbing large forces and acting as a buffer to
shock. This conformational change is temporary and after
1School of Pharmacy, University of East Anglia, Norwich, United Kingdom.
2Norfolk and Norwich University Hospital, Norwich, United Kingdom.
3Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
4Neotherix Limited, York, United Kingdom.
5University of Leeds, Leeds, United Kingdom.
6School of Biological Sciences, University of East Anglia, Norwich, United Kingdom.
ª Grace Walden et al., 2017; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative
Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited.
TISSUE ENGINEERING: Part B
Volume 23, Number 1, 2017
Mary Ann Liebert, Inc.
DOI: 10.1089/ten.teb.2016.0181
44
D
ow
nl
oa
de
d 
by
 U
N
IV
 O
F 
EA
ST
 A
N
G
LI
A
 fr
om
 o
nl
in
e.
lie
be
rtp
ub
.c
om
 a
t 0
8/
14
/1
7.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
the stimulus has receded, the tissue is able to revert to the
characteristic crimped formation once again.9 The resistive
capability of tendons is, however, not infinite, and if the
stretching limit is exceeded, this formation is lost and the
tissue becomes vulnerable to both micro- and macroscopic
tears,8 as shown in Figure 1.
Basic Tendon Anatomy
Tendons are formed from the continual aggregation of the
smallest structural unit, collagen, into an increasingly complex
architecture. Spontaneous aggregation of multiple collagen
molecules results in the formation of collagen fibrils, which are
aligned in a quarter-staggered array.8 These fibers then con-
tinually agglutinate to form progressive hierarchal structures
beginning with a collagen fiber, leading to a primary fiber
bundle, also known as a subfascicle, a secondary fiber bundle,
termed a fascicle, a tertiary fiber bundle, and, ultimately, the
tendon unit.9–11 This structure is highlighted in Figure 1.
Collagen type I accounts for 95% of total collagen in the
tendon,8 and for 60% of the total dry mass of the tissue.7
Highly organized and aligned, with stable crosslinks through-
out,12 it is representative of the mature form of collagen fi-
brils.13 The highly organized packing of collagen type I and
hierarchical architecture confer on tendons the ability to stretch
on mechanical stimuli and to absorb the resulting forces, en-
abling locomotion.10 The tenocytes present in tendon tissue
have the ability to respond to stimuli and are able to remodel
its microenvironment in response to stresses and strains. This is
mediated by the action of matrix metalloproteinase and is es-
sential for the repair, development, and function of the tendon
tissue.12 Comprising proteoglycans, glycosaminoglycans, gly-
coproteins, and collagens,8,14 the extra cellular matrix (ECM)
has a multitude of functions. By retaining large amounts of
water, the ECM acts as a lubricant to surrounding tissues,
ensuring the easy gliding of fibers during mechanical defor-
mation.5,9 In addition, it confers elasticity, provides cell ad-
hesion sites, and binds secreted growth factors.14
Tendon Repair and Regeneration
The repair of tendon tissue is hindered by its inherit low
cellularity and metabolic activity.11 The predominant cell
type found in tendon tissue is the elongated fibroblast-like cell
that is known as the tenocyte.12 Widely used markers for
tenocyte characterization such as Smad, scleraxis, tenomo-
dulin, and collagen are nonspecific and are expressed in most
cells present within tendon tissue. This makes their charac-
terization extremely difficult and, thus, hampers the clinical
translation of in vitro results. In addition, tendon stem cells
(TSC) express a multitude of markers that are also found in
both mesenchymal and embryonic stem cells.15 It has been
suggested that to fully characterize tenocytes, cells must ex-
hibit a combination of spindle-shapedmorphology, combined
with positive expression of markers such as collagens, dec-
orin, scleraxis, and Tenomodulin, while also being negative
for chondrogenic, osteogenic, and adipogenic markers. Cur-
rently, more work is needed to find this ideal panel of markers
for tendon-specific cell characterization.2,16
Tenocytes account for as much as 95% of the cellular
composition of the tissue7,10 and are situated within the
aligned collagen fiber bundles and the epitenon and en-
dotenon.12,17 These cells are responsible for the synthesis of
collagen, essential for the hierarchical architecture of the
tissue, and extracellular matrix components.11,18 The further
5–10% of cellular composition comprises progenitor cells,
FIG. 1. Showing tendon structures (physiological, tendinopathy, and tendon rupture) and stress–strain curve for tendon tissue.
(a) Illustrating the tendon sub-structures (including fascicles, fibers, fibril, and tropocollagen), with relative dimensions thereof in
a healthy tendon (top-left), and scar tissue formation in tendinopathy (middle-left)—characterized by disorganized collagen
fibers, scar tissue formation, and tendon rupture (bottom-left) in which the two ends become separated and frayed. (b) A stress–
strain curve for tendon tissue. At strains up to 2%, the tendon retains a characteristic crimped structure; this is known as the toe
region. Under mild mechanical loads and stresses below 4%, the tissue is able to lengthen its crimped collagen fibers and
withstand forces. This is known as the linear region, and it is representative of the physiological range of the tendon tissue. Strains
above 4% can result in small micro-tears within the tissue, and tendinopathy can develop. Repeatedmicro-tears and strains above
8% can result in the tissue rupturing. The blue dotted line depicts the toe, linear and failure regions on the stress/strain curve.
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chondrocytes that are necessary for enthesis formation, sy-
novial cells, and vascular cells, including smooth muscle
and endothelial cells that are needed for blood vessel de-
velopment.10,12 Once tendons have been subjected to ex-
cessive strain, the healing process is initiated. Currently, two
mechanisms of healing, intrinsic and extrinsic, are believed
to occur after injury.11 Most repair is believed to be via the
intrinsic pathway where proliferation of fibroblasts from the
epitenon and endotenon occurs, resulting in cellular migra-
tion to the site of the lesion and the synthesis of new matrix
materials.11,19 The extrinsic pathway is associated with
migratory inflammatory cells and fibroblasts from sur-
rounding tissues.11,19
The healing process consists of three overlapping phases:
immediately after injury when hematoma formation and an
inflammatory response occurs, followed by a repair process
characterized by an increase in myofibroblasts and synthesis
of new matrix materials, and, finally, a maturation and re-
modeling stage.19 In tendons, this remodeling process can
last up to 1 year, and it results in a structurally and bio-
mechanically inferior tissue that is characterized by disor-
ganized, aberrantly aligned collagen and the presence of
scar tissue.20 Healed tendon tissue is no longer comparable
to its native form and the random alignment of synthesized
collagen fibers, the disorganized matrix, and an increase
in collagen type III lead to impaired function of the
tissue.7,10,21,22 For the patient, this results in a reduction of
mobility23 and an increase in pain and morbidity. Overall,
the tendon is weaker and prone to rupture and tears,19
making it more likely for the clinical condition, known as
tendinopathy, to develop.
Tendinopathy
Tendinopathy is the umbrella term used to describe a
broad spectrum of several different tendon pathologies24
resulting from overuse and excessive mechanical loading,
preventing the tissue from being able to withstand further
tension.8,25 Most tendinopathies are not caused by one sin-
gle factor, and there are many contributory elements that can
be either intrinsic or extrinsic.26 These can include age,
gender, disease, occupation, and physical training.10,26
Tendinopathy can be classified as either acute, resulting
from excessive overload, or chronic, due to a degenerative
condition that is persistent over time.14 This explains the
tendency for tendinopathy to occur in both young patients
with active lifestyles and the elderly.27 Degeneration and
consequently repeated microtrauma are considered the pri-
mary causes of chronic pain-free tendinopathy. As a result
of continual tearing and failed healing attempts, the tissue
that remains is weaker and at risk of ‘‘spontaneously’’
rupturing.20,26 It has been suggested that in as many as 97%
of spontaneous ruptures, an underlining degenerative pa-
thology was pre-existing before the incident28
The tissue formed after tendon injury is altered in both its
structure and its composition. Degenerative tendinopathy is
associated with a decrease in collage type I, which is in-
dicative of a weakened tendon and results in decreased
tensile strength and ability to withstand mechanical load.29
In addition, injured tendons exhibit increased expression of
collagen type III. Collagen type III has fewer crosslinks19,30
and fibers that are smaller and thinner compared with col-
lagen type I, with a decreased resistive capacity.31 Tendon
tissue produced after healing, abundant in Collagen type III,
is much less organized, which is believed to be attributable
to a loss of structure and a decreased mechanical strength.8
In healthy tendon, it is synthesized at significantly lower
levels in comparison to collagen type I.30 However, in ag-
ing, degenerative, or stressed tendon, it is upregulated and
synthesized in abundance during the repair process.13,30 An
increase in the production of collagen type III, relative to
type I, is believed to lead to the formation of adhesion sites.
Adhesion sites result in inadequate lubrication between the
tendon and surrounding tissues, causing friction and pain.32
These hinder the gliding of the tendon and account for its
reduced mobility seen after injury.33,34 Increases in collagen
type III are also associated with reduced mechanical
strength, risk of rupture, and, ultimately, the formation of
scar tissue.30 Likewise, tendinopathies are characterized by
a broad range of cellular and molecular differences from the
native tissue.12 Decreased cellularity is prominent, resulting
from apoptosis of tenocytes.35 Conversely, tendinopathy can
also exhibit hypercellularity,36 particularly in the case of
tendinosis and chronic tendon pain. On injury, the cells can
respond to intrinsic and extrinsic signals by increasing
proliferation. These cells are often altered in morphology
when compared with healthy tenocytes.37 Matrix organiza-
tion is aberrant. Abnormal vascularity is present; the protein
content and composition is altered, with an increase in
tenascin-C and fibronectin and a decrease in decorin ex-
pression.19
Current treatment options for tendon injuries are mainly
conservative, focused on the management of pain rather
than on the healing of the underlying damage.12 Non-
steroidal anti-inflammatory drugs such as ibuprofen are
used, where inflammation is a key component, for example,
tendinitis. Exercise and mobilization therapy is generally
recognized to be of benefit, with stretching and strength-
ening activities being the most commonplace.38 Surgery is
considered the last resort and is used for the treatment of
tendinopathy when conservative therapy has failed.39 Rup-
tures resulting in lesions greater than 5mm have limited
healing capacity and result in loss of function of tissue,
meaning that surgery is usually the only option, notably in
fit and active patients. Surgical treatment aims at bringing
the repaired tendon back to its original length by excising
the necrotic tissue and suturing the ends together.40 The
remaining tendon, however, is often plastically deformed
and therefore not as mechanically strong as the normal
tendon. However, re-rupture is common in many affected
tendons; in the rotator cuff, it has been reported to be as high
as 94%.22 Long-term outcomes for patients are highly var-
iable,19 and morbidity remains high even after so-called
‘‘successful’’ treatment.11 In addition, further complications
postoperatively are prevalent, such as the increased risk
of early onset osteoarthritis, chronic pain, and in the case of
allografts, the risk of immune rejection. Surgery is yet to
yield consistently satisfying results without the presence of
pain, reduced patient mobility, morbidity, or high risk of re-
rupture for patients.39 Overall, there is no accepted standard
treatment option for tendon injuries, and there is an obvious
unmet clinical need. The current therapies are not supported
by satisfactory clinical trials, are not effective,14 and fail
to address the underlying associated pathophysiological
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pathways.27 When considering the current treatment options
available, the need for the development of a successful
system that incorporates the knowledge of the native tissue
and that aims at addressing the underlying pathological issue
with the goal of a regenerative outcome is apparent.8
Biological and Biomaterials Approaches
in Tendon Regeneration
The emerging field of Tissue Engineering and Re-
generative Medicine is increasingly being employed to design
strategies for the repair of tendon tissue. These strategies are
focused on the activation and enhancement of the body’s own
repair system by using a combinatory approach that may in-
clude the application of cells, stimulatory factors, genes, and
scaffolds.41 Tissue engineering is evolving toward the pro-
duction of functional ex vivo tissue manipulating the use of
bio-responsive scaffolds,42,43 which can be implanted at the
injury site, for in situ formation of de novo tissue.44 Recent
attempts have been made both in vivo and in vitro to assess
the advantages of delivering cells, genes, and proteins to
tendon defects to recapitulate the complex signaling process
seen in the natural healing of tendon tissue.23
Cell-Based Therapy in Tendon Regeneration
One idea recently emerging in the field of tissue engineering
is that the delivery of cells that are capable of synthesizing
matrix materials may prove effective for the healing of tendon
tissue.45 Different cell sources have been investigated, in-
cluding tissue-specific cells such as tenocytes,35,32 and TSC2,46
as well as ‘‘nonspecific’’ mesenchymal cells11,17,33,47,48 de-
rived from multiple sources, including bone marrow and adi-
pose tissue. Direct injection of cells is proving promising, with
several clinical trials underway. In one trial, an autologous
tenocyte injection into the site of severe tendinopathy of the
common extensor tendon in 20 patients that was associated
with chronic lateral epicondylitis was performed.35 Overall,
the outcome was one of improved function and improved re-
pair of the tendon tissue. Patients reported an 86% improve-
ment (i.e., reduction) in pain after treatment. Similarly, results
from tests aimed at assessing the disabilities of the arm,
shoulder, and hand improved by 91% compared with pre-
intervention scores. In addition, magnetic resonance imaging
(MRI) data aimed at grading the severity of tendinopathy
showed a decrease in severity after treatment.35 However, this
study used only a small sample size, with no control group and
the level of evidence is four, which is deemed low. In addition,
improvements were seen when comparing patient data based
on the opinions of the patient rather than on histological ex-
amination of the injury. In fact, MRI data showed that in some
patients the injury had worsened and needed further treatment.
Dermal fibroblasts, an abundant and readily accessible cell
source, have also been used in therapies for tendon regenera-
tion.49 Twelve patients diagnosed with refractory lateral epi-
condylitis were treated with laboratory-prepared cells derived
from dermal fibroblasts. After 6 months, a reduction was ex-
hibited in the number of tears, angiogenesis, and tendon
thickness. Recovery in 11 of the patients treated was deemed
satisfactory, with ultrasonography results indicating the pres-
ence of tendon tissue resembling the native state.50 Forty-six
patients suffering from refractory patellar tendinopathy were
treated with ultrasound-guided injections of autologous skin-
derived cells. Pain, severity of tendinopathy, and functional
disability scores were measured; these improved from 44 to 75
points at 6 months post-treatment, which was consistent with a
reduction in disability and pain for the patient.49
Preclinical animal studies have also shown promising re-
sults. Autologous tenocyte preparations were injected into ar-
tificial collagenase-induced chronic tendinopathy in rabbit
Achilles. Production of collagen type I but not type III was
increased, and these fibers were highly organized and aligned.
The tissue produced had a tendency to be stiffer when com-
paredwith nontreated control groups.51 In equinemodels, bone
marrow-derivedmesenchymal stem cell (BM-MSC) treatment
has resulted in a quicker recovery time and a reduction in re-
injury rates.52,53 Autologous BM-MSCs suspended in bone
marrow supernatant were injected into damaged digital flexor
tendons of 12 race horses. Treated animals displayed improved
tendon stiffness, and a return of characteristic crimp formation
of tissue along with a recovered organization. Improved his-
tological scoreswere recorded, and thesewere accompanied by
decreased vascularity, water content, swelling, and MMP-13
activity. The cross-sectional area of tendons remained signifi-
cantly smaller than control groups treated with saline alone.
Overall, repaired tendons showed histological and biome-
chanical properties that were more similar to those of un-
damaged tendons when compared with untreated groups.53
Similarly, racehorses considered to have career-ending
tendinopathy showed improved healing when treated with
BM-MSC. An intralesional injection for naturally occurring
tendinopathy of the digital flexor tendons was administered
in 113 racehorses. After 3 years, 98.2% had returned to
racing and re-injury rates were lower than with conservative
treatments alone. This study concluded after long-term
follow-up that the implantation of BM-MSC was both safe
and effective for the treatment of tendinopathy.52
Combinatorial approaches have been investigated for the
delivery of cells and proteins simultaneously. When injected
in combination with platelet-rich plasma (PRP), adipose-
derived stem cells (ADSC) led to the production of neo-
tendon that was comparable to healthy tissue. Alignment of
tendon fibers and significant reductions in lesion size were
reported. Horses treated in this manner were able to return to
competitive activity, and ultrasound data indicated the for-
mation of neo-tissue that was comparable morphologically
to healthy tendon, suggesting the initiation of a regenerative
healing process.54 Current advances in cell-based therapy
for tendon tissue regeneration are highlighted in Table 1.
One of the biggest issues surrounding the use of cells for
regenerative therapeutic is finding the most appropriate
source, each having their own specific limitations,2,17 and
currently there are no standard cell culture conditions
available, meaning that in vitro and in vivo conditions used
always differ. Tenocytes are the predominant cells in tendon
tissue that have been studied extensively. The major issue
surrounding the use of tenocytes is that they have a very
limited availability, and the use of allografts can lead to
morbidity at the donor site.55 After harvesting, issues can
then arise in cultures with multiple passaging, leading to a
loss in tenogenic markers, phenotypic drift, and a reduction
in metabolic activity.2 TSC also have limited availability
and are susceptible to a loss of phenotype during expansion;
currently, these cells have not managed to show enough po-
tential to warrant large preclinical animal model investigation.
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Similarly, the implantation of TSC alone only led to minor
tendinous tissue formation.46 The use of nontendinous cell
sources such as dermal fibroblasts or muscle cells can often
result in complications and concerns surrounding tissue
specificity. The use of stem cells has been linked to ectopic
bone formation; they require specific tenogenic differentia-
tion in vitro before use, which can often be complicated. In
addition, multiple cultures can result in the loss of stemness.
Currently, there is a lack in a panel of tendon-specific
markers for identification. Characterization usually relies on
the presence of a whole host of transcription factors related
to tendon differentiation, but lacking specificity such as
scleraxis, or ECM proteins such as collagens and tenomo-
dulin.2 For example, TSC express the same panel of markers
needed to characterize MSCs according to the international
society for cellular therapy,56 and many factors can influ-
ence the expression of these markers, including age of the
cell source, the donor tendon, and culture protocols.15 The
exact mechanism of ADSC is unknown, and it, thus, pres-
ents the risk of unpredicted hazards if used in a clinical
setting. In addition, studies have shown that increases in
aggrecan that are seen suggest that these cells differentiate
toward a more chondrogenic linage. The use of cells for the
regeneration of tendon tissue is also extremely cost inten-
sive, and current clinical trials show either low levels of
evidence or only minor benefits.
Table 1. Current Advances in Cell-Based Strategies for the Regeneration of Tendon Tissue
Cell line Tendon model Results Type of study Ref.
BM-MSC Equine Improved tissue organization. Formation
of crimp structure. Histological
improvement of tissue, including
reduction in GAG, DNA, and cell
content, comparable to ‘‘normal’’
tendon.
In vivo/in vitro 53
ADSC Rabbit Achilles
tendon
Neo-tendon formed, with tensile strength
comparable to 60% of normal tendon.
Production of parallel collagen fibers
and elongated cells aligned
longitudinally with collagen fibers.
In vivo/in vitro 55
ADSC Rabbit Achilles
tendon
Increased tensile strength of tendon tissue.
Partially regular and longitudinal
alignment of collagen fibers. Increased
collagen type I production.
In vivo/in vitro 29
Tenocytes Human extensor
carpi radialis
brevis tendon
Improvement of patients’ pain score
by 86% after 12 months. Improved
grip strength. Reduction in clinical
prevalence of tendinosis. Functional
improvement and structural repair
of tendon.
Clinical trial
evidence
level 4
35
Tenocytes Rabbit Achilles
tendon
Increased collagen type I expression,
demonstrating enhanced alignment.
Increased stiffness of tissue.
In vivo 102
Dermal Fibroblast Human patella refractory
tendinopathy
Pain, severity, and functionality scores
improved from 44 to 75 after 6 months.
Decrease in tendon thickness.
Randomized
controlled trial;
level of
evidence, 1
49
Muscle-derived
stem cells
Mouse muscularis
fascia of dorsum
Formation of cord-like neo-tendon similar
to native tissue in appearance.
Increased maximum load capacity.
Increased stiffness at 12 weeks.
Increased tensile strength.
In vivo 102
Tendon stem cells Rat patella tendon Increased expression of collagen type I
and III, and tenomodulin. Formation
of tendon-like tissue after 8 weeks.
Enhanced collagen fiber thickness.
In vivo/in vitro 46
Fibroblast Rabbit infraspinatus
tendons
Increased type I collagen expression.
Increased tensile strength
of regenerated tissue.
In vitro 103
Periosteal
progenitor cells
Rabbit infraspinatus
tendon
Increased matrix deposition. Increased
production of aggrecan and collagen
type I and II. Formation of
fibrocartilage and bone at the
tendon–bone insertion site.
In vivo 102
ADSC, adipose-derived stem cells; BM-MSC, bone marrow-derived mesenchymal stem cell; GAG, glycosaminoglycan.
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Proteins-Based Therapy in Tendon Regeneration
One of the potential therapeutic approaches emerging
for the regeneration of tendon is the sustained release of
cytokines and growth factors.57,58 The use of exogenous
growth factors presents the possibility of accelerating cell
proliferation, collagen synthesis, and extracellular matrix
synthesis, leading to quicker recovery and enhanced re-
pair.1,34,59 Several growth factors are currently being
studied for this purpose (Table 2). These include insulin-
like growth factor, platelet-derived growth factor, basic
fibroblastic growth factor, bone morphogenetic proteins
(BMP), transforming growth factor beta (TGF-b), and
vascular endothelial growth factor (VEGF).23 All have
been shown to be expressed and are important in nearly
every phase of healing progression.33,60 VEGF-111 was
evaluated for its potential to enhance tendon healing in rat
Achilles tendon. A local injection of VEGF-111 resulted in
an increased force to failure and ultimate tensile strength
from a single dose.61 Furthermore, the continuous slow
release of VEGF caused increased vascularization, result-
ing in accelerated healing of the tendon-to-bone insertion
site of patients with rotator cuff injuries.62 VEGF is well
known to stimulate angiogenesis.63,64 It is important in the
early phases of tendon healing and it increases the vas-
cularity of tissue and the corresponding proliferation of
endothelial cells.21 In acute tendinopathy of patella ten-
dons, patients exhibited a higher VEGF expression when
compared with those suffering from the chronic condition.
This has led to the suggestion that an increase in VEGF
expression may lead to an accelerated healing after acute
injury, especially when mechanical load is kept to a min-
imum.64 Current data suggest that VEGF has the potential
to increase the tensile strength of tendon and to augment
the healing process.65 However, contradictory research
exists that questions whether increased vascularization is,
indeed, beneficial. It has been suggested that a relationship
may exist between neovascularization and pain in Achilles
tendon. Areas of increased pain and palpable tenderness
are heavily correlated with neovasculature within the tis-
sue, suggesting that an increase in vascularization would,
in fact, be detrimental.66 It is also possible that increased
vascularization is limited in its application to early tendon
healing alone, with insufficient numbers of studies and
clinical trials being carried out thus far.62 Correspond-
ingly, the current opinion of the benefit of VEGF as a
therapeutic agent for the regeneration of tendon tissue is
still inconclusive, requiring further investigation and evi-
dence of improved clinical outcomes. When TGF-b3 was
delivered to the repair site of supraspinatus tendon-to-bone
insertions of rats, cell proliferation, vascularity, and an
accelerated healing process were observed. Blind evalua-
tion indicated an increase in cellularity at 14 days of ten-
dency toward a stiffer tissue, an increase in ultimate
strength, and a decreased cross-sectional area. The results
of this study demonstrated the ability of TGF-b3 to sig-
nificantly increase the biomechanical and structural prop-
erties of the tendon, leading to a better quality tissue when
compared with controls.67,68
However, as with the delivery of cells, therapies requiring
the delivery of proteins have their own limitations. Problems
are often encountered when attempting to deliver the ther-
apeutic agent to the target site, as they need to escape
degradation that is long enough to be effective. Current
applications for growth factors are limited by the short half-
lives of these molecules,1,21 and by the lack of protein re-
tention at the repair site.69 This highlights the need for an
effective delivery system that is able to retain growth factors
and cells at the site of injury, with continued controlled
release, and allow the sequential administration of different
Table 2. Current Strategies for the Delivery of Exogenous Growth Factors
for the Regeneration of Tendon Tissue In Vivo
Treatment Tendon model Results Ref.
PDGF-BB Canine flexor tendon Increased cell density and proliferation. Increased
expression of collagen type I. Thirty percent increase
in reducible crosslinks.
104
PRP Equine superficial digital
flexor tendons
Increased cellularity. Increased collagen and GAG content.
Increased tensile ability. Increased collagen matrix
integrity.
74
VEGF-11 Rat Achilles tendon Increased ultimate tensile strength of tendon. Increase
in mechanical stress needed to rupture healed VEGF
tendons compared with controls.
61
IGF-1 and TGF-b Rabbit patellar tendon Increased vessel formation. Production of fibrous repair
tissue, with enhanced orientation. Increased force
at failure, ultimate stress and stiffness at 2 weeks.
68
BMP-12 protein Sprague–Dawley rats
calcaneal tendon
Increased expression of tenocyte lineage markers
such as Scx and Tnmd. Formation of tendon-like tissue.
Increased cell proliferation. Elongation and alignment
of cells, and increased matrix deposition.
105
BFGF Rat Rotator cuff tendon Increased production of GAG. Improved collagen
organization, stiffness, and ultimate load to failure
8 weeks postoperatively. Improved healing at enthesis.
106
A more extensive review of this is covered elsewhere.4
BFGF, basic fibroblastic growth factor; BMP, bone morphogenetic protein; PRP, platelet-rich plasma; VEGF, vascular endothelial
growth factor.
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factors. A suitable delivery system will offer the benefit of
lowering the effective treatment dosage as well as of re-
ducing the number of injections necessary for positive out-
comes.21,70
The optimum delivery platform for proteins and growth
factors is yet to be identified. Recombinant growth factors
have a very short half-life when in physiological conditions,
and they are quickly cleared from the site of injection. This
means that very high doses are required to be clinically
efficacious or multiple injections are needed, leading to high
costs and encumbrance to patients.21 One of the biggest
questions researchers must answer is what is the safest and
most efficacious does, and this will change depending on the
number and type of growth factor being employed in each
formulation.70 Currently, the use of growth factors sparks
controversy within the field, with bodies of research both
advocating and refuting their use. Each deliverable factor,
although with its advantages, is not without limitations. For
example, the use of PRP is surrounded by a large amount of
controversy within the field, with several newer studies
suggesting that it has little to no benefit when compared
with saline injections alone. A recent double-blind ran-
domized clinical trial where patients were given ultrasound
guided injections of either PRP or saline revealed that even
after follow-up at 1 year no significant differences were seen
between the two groups.71 In addition, there is currently
some concern over the potential for PRP to secrete inflam-
matory mediators, which would have a negative impact on
healing.64 Complications also arise when considering the
reproducibility of results; due to the high diversity seen
between each batch of PRP, more work is needed to as-
certain the most efficacious production protocol.59 One of
the possible explanations for this inconsistency seen in the
application of growth factors is that in vitro results are not
successfully translated to improvements in vivo.34
Furthermore, most studies into the benefit of injectable
growth factors have employed the use of a single factor and,
as such, there is a large range of controversy with variable
results. The use of a single factor may prove to grossly
oversimply the complex processes needed to fully stimulate
the healing of tendon tissue.63 Considering the complex
cascade of events that occurs during the healing of tendon
tissue, it is likely that a multitude of factors will need to be
applied at one time, the optimum cocktail has not yet been
identified, and a multitude of possibilities exist.65
Considering that tendon repair is a lengthy process and
the final stages are often not reached until after a year after
injury, animal studies have a limited duration. In addition,
due to the nature of tendon injury, a wide variety of lesions
are likely to occur in patients that are not recreated during
in vitro testing, with most injuries being due to direct sur-
gical input or via enzymatic degradation, which does not
successfully represent real injury.72
Gene-Based Therapy in Tendon Regeneration
Gene delivery is designed to supply exogenous genetic
materials into cells to alter the DNA and to induce, silence,
upregulate, or downregulate the expression profile and se-
cretion of proteins.73,74 Gene delivery has the advantage of
resulting in the production of proteins that are synthesized
naturally by host cell mechanisms, and, as such, is not as-
sociated with reduced bioactivity and activation of an im-
mune response, which is often encountered when delivering
exogenous biomolecules.4 In addition, gene delivery provi-
des the opportunity for long-term protein release and
availability, reducing the need for multiple injections of
external factors and excessive therapeutic dosages. How-
ever, despite these advantages, gene delivery is limited by
the susceptibility of nucleic acids to degradation and attack
by immunocytes. If not sufficiently protected, naked nucleic
acids are quickly destroyed and do not survive extended
periods of time in plasma.75 This coupled with the chal-
lenges associated with efficient uptake of nucleic acids into
host cells make it necessary for a suitable delivery system to
be used for the effective delivery of small interfering RNA.
In the past few years, several studies have focused on
establishing gene delivery systems for the healing and re-
generation of tendon tissue (see Table 3). Plasmid DNA-
encoding fibromodulin with histidylated liposomes and
histidylated liner polyethylenimine polycomplexes were
transfected by using a rat Achilles tendon laceration model.
The results showed that, based on stiffness and histological
analysis, treated tendons demonstrated an enhanced healing
response that resulted in a tissue that was more phenotypi-
cally similar to healthy tendon than control groups.76 In a
further study, adenovirus promoting the expression of BMP-
14 was transfected into the rat Achilles tendon laceration
model. Histological and biomechanical effects were exam-
ined, and results showed that tendon treated with transfec-
tion exhibited 70% greater tensile strength and increased
cellular proliferation of tenocytes when compared with
control groups at 2 weeks postrepair. No inflammatory re-
sponse or production of undesired bone or cartilage forma-
tion was observed as an effect of adenovirus.77
Gene delivery systems have also been assessed for their
ability to downregulate the expression of proteins and to
reduce adverse effects of tendon healing such as the for-
mation of scar tissue (see Table 4). Rat patellar tendon cells
were transfected with lentiviral-encoded shRNA (small
hairpin RNA) to specifically silence the expression of dec-
orin. Histological and biomechanical studies showed that
downregulation of decorin to an appropriate level can pro-
mote the repair and regeneration of patellar tendon, and it
can result in a reduction in scar formation.78 Down-
regulation of the intra-synthesis of TGF-b1 can be beneficial
for the regeneration of tendon tissue. A poly lactic-co-
glycolic acid (PLGA) nanosphere delivery system that can
incorporate plasmids was shown to specifically inhibit the
expression of TGF-b1. The PLGA nanospheres were able to
effectively deliver the plasmid into tenocytes and to inhibit
the expression of TGF-b1, with an effect lasting more than 6
weeks. This resulted in an improved tendon healing.79
Adenovirus-mediated gene transfer has been studied in
healing rat Achilles tendon and in human rotator cuff tendon
cells in which the adenovirus vector resulted in successful
transfection of LaCZ gene into tendon cells. Similarly, ad-
enovirus vectors have been used for the delivery of exoge-
nous FAK gene and BMP-12 gene into chicken tendon cells,
resulting in a significant increase in expression of these
genes when compared with controls, and in an enhanced
healing of tendon tissue.80,81 Abbah et al. conducted studies
by using plasmid DNAs encoding decorin and interleukin-
10 to co-transfect human tenocytes using polyplexes to
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suppress the expression of TGF-b and demonstrated positive
results in vitro.82 Delalande et al. used liposomes and
polymersome as delivery vectors and demonstrated im-
proved mechanical tendon strength after transfecting with
plasmid DNA encoding fibromodulin in an in vivo model.78
Although gene-based therapy has shown great potential in
treating tendon injury and degenerative conditions, how-
ever, there are still concerns regarding the safety profile of
genetic materials, such as potential mutagenicity associated
with the use of plasmids.83 On the other hand, the use of
viral vectors is problematic and has been known to cause a
serious immune response. On the contrary, the nonviral
vectors are reported to have a safer profile but have a di-
minished transfecting capacity.84 Further work needs to be
carried out to advance the current field toward developing
more effective transfection materials with either no or
minimal toxicity.
Clinical Perspective and Delivery Platforms
for Tendon Tissue Regeneration
To mimic successfully the spatiotemporal signaling pro-
file seen in the healing process of tendon tissue, suitable
biomaterials are needed to act as a delivery and supporting
template for the sustained release of proteins, genes, and
cells85 and to provide an architecture for cells moving into
the site of damage.20,86 Current tendon tissue regeneration
strategies are highlighted in Figure 2. Scaffolds can be used
either as mechanical support or as carriers for deliverable
factors. The main aim of the biomaterial scaffold is to
Table 4. Use of Gene Transfection as an Advanced Delivery System for Tendon
Healing and Corresponding Vectors
Gene Vector Delivery mode Animal model Ref.
BMP-2, Smad8 Liposome In vitro Rat, Achilles 120
BMP-14 Adenovirus In vivo/in vitro Rat, Achilles 79
TGF-b1 Nanospheres In vivo/in vitro Chicken, flexor tendon 114
Gal HVJ-liposomes In vivo/in vitro Rat, patellar 121
Lac Z Adenovirus In vitro Rat Achilles, human rotator cuff 82
HVJ, hemagglutinating virus of Japan.
Table 3. Genes Related to Tendon Regeneration and Their Function4,107–109
Gene symbol Corresponding molecule Primary function Ref.
COL1A1 Collagen type I Extracellular matrix structural constituent synthesis;
identical protein binding.
107,110
COL3A1 Collagen type III Extracellular matrix structural constituent synthesis;
identical protein binding.
12,107
COL5A1 Collagen type V Extracellular matrix structural constituent synthesis;
identical protein binding.
111,112
TNC Tenascin-C Encodes an extracellular matrix protein. 5,107
ACAN Aggrecan Encodes an extra cellular matrix protein; mutations
in this gene may be involved in skeletal degeneration.
5,12
MMP Matrix metallo-proteinase Proteins of the MMP family are involved in the hydrolysis
of extracellular matrix in healthy tissue.
4
TGFB1 Transforming growth factor beta 1 Encodes a member of the TGF-b family of cytokines. 113,114
IGF-1/IGF-2 Insulin-like growth factor Encodes IGF-1/IGF-2, which is processed from a precursor,
bound to a receptor, and then secreted.
115
PDGFA/PDGFB Platelet-derived growth factor
alpha/beta
Encodes PDGFA/PDGFB. 116
ELN Elastin Encodes elastin, an extracellular matrix structural
constituent.
108,109
FBN2 Fibrillin 2 Encodes fibrillin 2, an extracellular matrix structural
constituent.
108,109
LAMA4 Laminin alpha 4 Encodes laminin alpha 4, a family of extracellular matrix
glycoproteins, which are the major non-collagenous
constituents of basement membranes.
108
Scx Scleraxis This gene encodes a protein that is expressed during
embryonic development of tendons and ligaments.
117,118
Tnmd Tenomodulin This gene is also a candidate gene for age-related macular
degeneration, though a direct link has yet to be
demonstrated.
118,119
Fmod Fibromodulin The encoded protein may play a role in the formation
of extracellular matrix and also regulate TGF-b level.
78
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provide a suitable environment for the attachment, prolif-
eration, and migration of cells and to provide a foundation
for matrix remodeling and tissue regeneration.41 The ideal
biomaterial will closely mimic the native ECM architecture
and biomechanical properties of tendon tissue.44 The bio-
material may be designed to incorporate cell adhesion
moieties that allow for interaction with the host tissue, as
well as for containing enzymatically sensitive regions that
enable the degradation of the scaffold to occur simulta-
neously with de novo tissue formation. In addition, the ideal
biomaterial would easily incorporate morphogens, signaling
molecules, and cells that are able to co-ordinate the native
healing process that results in the regenerative repair of the
tissue.44 Biomaterials can include either natural or synthetic
polymers, with some of the most common being collagen,
chitosan, gelatin, alginate, hyaluronic acid, polyethylene
glycol, polycaprolactone (PCL), polyglycolide, and PLGA.87
The precise biomaterial used and the scaffold structure can be
altered to meet the requirements of the tissue, the deliverable
factor to be encapsulated, for example, cells, proteins, or
genes, and the implantation method into the host tissue.
Injectable Hydrogels Systems
Hydrogels have potential as a biomaterial scaffold for the
delivery of regenerative morphogens. Their polymeric net-
works can be easily functionalized and manipulated to have
desired properties such as easy injection, mechanical stiffness
and strength, and a controllable degradation rate.88 The
polymer networks are hydrophilic with large water-absorbing
capacity, and so are both biocompatible and able to closely
mimic tendon ECM. They can be stabilized by using a
number of crosslinking techniques or designed to be tem-
perature or pH sensitive.
Hydrogels manipulated to encapsulate proteins and cells for
their controlled delivery have been investigated in tendon
models.51,89 An injectable poly (ethylene glycol) diacrylate
hydrogel system was used for the delivery of BMP-2 protein
and periosteal progenitor cells to defects at the tendon-to-bone
interface of rabbit infraspinatus tendon. The hydrogel was able
to fill successfully the defect, and the controlled release of
regenerative factors resulted in the formation of fibrocartilage
tissue around the tendon–bone interface after 4 weeks. Col-
lagen type I production also increased around the tendon.
Overall, the injectable hydrogel was able to increase the mat-
uration and fibrocartilage formation around the tendon-to-bone
interface, resulting in an improved healing response.51
Oligo(poly(ethylene glycol) fumarate) (OPF) and acry-
lated poly(ethylene glycol)–dithiothreitol (Ac PEG-DTT)
hydrogels were produced with controlled degradation times
ranging from a few days to 1 month. These were implanted
into bovine patellar tendon defects in vitro to assess the
ability of MSCs to infiltrate the area. It was found that by
making these hydrogels degradable, the MSCs were able to
infiltrate the defect site completely and concomitantly with
degradation, whereas nondegradable structures resulted in
MSCs concentrated around the sides of the defects. This
suggests that hydrogels that can be controlled to degrade
alongside the release of MSCs will result in the production
of de novo tendon tissue that replaces the scaffold and fills
the entire defect area.89
Hydrogel membranes consisting of xanthan gum, gellan
gum, and hyaluronic acid were investigated for their ability to
stop adhesion formation after tendon repair. The hydrogel
membranes were placed into defects of the rat Achilles ten-
don, which were evaluated for histological and biomechani-
cal strength after 3 weeks. The hydrogel membranes were
able to degrade slowly and, thus, stayed present in the de-
fect site during the entire period of healing. This resulted in
much fewer adhesion formations and improved mechanical
strength.32 In a similar study, collagen hydrogels were com-
bined with electrospun fibers to produce a novel 3D hybrid-
ized collagen implant that was able to mimic tendon tissue in
both its size and architecture. These implants were then used
to fill Achilles tendon defects in 75 rabbits. When compared
with controls, implants demonstrated a decrease in adhesion
FIG. 2. Tissue engineering
strategies for tendon regen-
eration, including (a) inject-
able therapeutics containing
cells, proteins, or genes,
which can be directly in-
jected to the site of the injury.
(b) Regenerative implants
containing a combination of
cells, protein, and scaffold
materials, which can be di-
rectly implanted and sutured
in tendon rupture injuries.
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formation and muscle atrophy, and improved tissue align-
ment. In addition, the implant was fully degraded at the re-
modeling stage and was easily replaced with the newly
formed tissue. Overall, the implant was able to produce an
improved clinical condition, including tissue alignment and
reduction of adhesions, within the animals.90 The ease of
functionalizing hydrogels to have specific properties that can
be manipulated to suit the demands of the healing tissue and
deliverable factors is making them an increasingly popular
choice of biomaterial for regenerative medicine.
Injectable strategies are advantageous for smaller tendon
defects, benefiting as space-filling agents, as well as acting as
a sealant and a barrier to the formation of adhesion sites.32,91
Their space-filling abilities allows them to be easily incor-
porated into irregular defects without the need for surgical
intervention.92 They offer a simple and convenient method
for the prolonged and controlled delivery of regenerative
factors, and they allow for the proliferation and differentiation
of cells that are necessary in the treatment of small defects.93
They offer a minimally invasive, convenient method for the
prolonged delivery of cells and proteins to the defect site.94
Injectable systems have been advantageous in small lesions of
the tissue and in ruptures where the torn end of the tissue
proves difficult to re-suture, such as enthesis ruptures.
Implantable Fibers System
Implantable materials are preferred in larger defects where
the structural and mechanical properties of the tissue are
greatly diminished.93 Implantable materials are able to bridge
the gap created within larger midpoint ruptures, providing
surgeons with the ability to remove the necrotic frayed end of
the tissue, reconnect the tendon, and suture in place the re-
generative device. This is particularly useful for full ruptures,
and for partial ruptures that result in a large defect and
a shortening of the tendon. Strategies that involve the use of
a polymeric scaffold that is able to bear the mechanical loads
subjected to the tissue while healing is taking place are more
advantageous.93 Currently, implantable systems are more
commonplace in tendon repair than injectable ones. Bioma-
terials can be woven or electrospun into fibers that are easily
implanted into the defect site of tendon injury. Collagen has
been extensively studied to assess its effectiveness as a bio-
material scaffold for the delivery of cells and proteins. When
seeded onto electrochemically aligned collagen fibers, MSCs
were able to differentiate down a tenogenic lineage in vitro
and an increase in tendon specific markers such as scleraxis
and tenomodulin was recorded.94 Collagen type I fiber scaf-
folds were shown in vitro to be conducive to a proliferative
environment for tendon fibroblasts. It was found that by
producing synthetic fascicle structures of collagen type I
woven fibers, both tendon cells and white blood cells were
able to infiltrate the entire scaffold and to adhere to the sur-
face, with tendon tissue markers produced.86 In a similar
study, collagen electrospun fiber implants, crosslinked via ri-
boflavin and ultraviolet and combined with bovine platelet gel,
were introduced to largeAchilles tendon defects in rabbits. The
biomaterial implant induced an enhanced inflammatory re-
sponse, mediated by cells infiltrating the entire defect area and
resulting in improved healing. The addition of the platelet gel
to the collagen scaffold resulted in the increased proliferation
andmaturation of host fibroblastic cells, and, as such, increased
the production of tendon matrix. Overall, the result was im-
proved neo-tendon formation and healing. As the collagen
implant degraded, the neo-tendon was able to form, was con-
centrated at the wound site, and was accompanied by a re-
duction in adhesion formations and muscle fibrosis.95
Other natural polymers have been investigated as scaffolds
for tendon and ligament regeneration, including gelatin, fi-
brin, alginate, and chitosan.44 In an important study, elec-
trospun and highly aligned chitosan fibers were produced and
seeded with mesenchymal stem cells. Interactions with these
aligned fibers resulted in a morphological change of the MSC
toward a more fibroblastic phenotype. In addition, gene ex-
pression was altered, displaying a more tendon-specific pro-
file, including a 50-fold increase in collagen type I expression.
When these fiber scaffolds were implanted into rat Achilles
tendon defects, it was found that this biomaterial together
with the introduction of MSCs to the wound area resulted in
an improved healing response when compared with randomly
aligned fibers. Collagen expression, fibril diameter, stiffness,
and force at failure were all increased in tendons in which
aligned chitosan fibers were used.96
The use of synthetic polymers as biomaterials has also
been investigated for the repair of tendon injuries.97 PGA/
PLA fibers were used as a scaffold for the implantation of
ADSC for the treatment of rabbit Achilles tendon, with
surgically created defects that were 3 cm in length. Scaffolds
consisted of an inner section of PGA fibers aligned longi-
tudinally, and an outer layer of knitted PGA and PLA fibers
to form a net-like structure. After in vitro expansion, ADSC
were evenly seeded onto fiber scaffolds. Animals were sacri-
ficed at 12, 21, and 45 weeks postsurgery. It was demonstrated
that the longer the scaffolds were available at the repair site,
the more improvement was seen, including the formation of
neo-tendon tissue. A histological examination of neo-tendon
confirmed similarities to native tissue, with an increase in
collagen alignment, fibril diameter, and tensile strength. Ten-
sile strength in the treatment group reached 60% compared
with normal tendon, whereas control groups remained at 23%.
In addition, cell-free control groups exhibited scaffold prod-
ucts at the repair sites at 45 weeks, fibrotic tissue, disorganized
collagen, and increased inflammatory cells.55
Similarly, PGA electrospun fibers were used to deliver
and to assess the ability of muscle-derived cells from mice
to promote the formation of neo-tendon compared with te-
nocytes as a control. Cells were seeded onto PGA fibers and
sutured to defects. Muscle cells were able to produce
stronger tendon tissue, with thicker collagen fibers exhibit-
ing increased maturity when compared with tenocyte-
generated tissue. After 12 weeks, the cells had lost expression
of muscle-specific markers such as MyoD and had an in-
creased expression of tendon-specific markers.98 PCL elec-
trospun fibers have been used in conjunction with silk fibroin
yarns. The PCL is able to provide mechanical strength to the
scaffold, and the silk fibroin yarns contain the crimp structure
that is characteristic of tendon tissue. Fibroblasts grown in
the presence of these constructs were able to proliferate at
increased rates compared with controls, highlighting the ability
of these biomaterials to promote and support cell growth.99
Fiber biomaterials are increasing in popularity due to their
relative ease of suture to the repair site, and their ability to
incorporate deliverable factors into prealigned structures re-
sembling native tendon tissue.
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Allograft Decellularized Tissue
Decellularized tendon is emerging as a promising bio-
material for tissue regeneration. Decellularized tissue has
the ability to exactly resemble the structure of tendon tissue
while being able to provide the appropriate adhesion and
signaling cues to host cells.100 As a scaffold, the decel-
lularized tissue is able to allow the growth of cells along the
aligned collagen fibrils present to mimic exactly the ECM
present in healthy tendon tissue, leading to an improved
healing response.101 Engineered tendon matrix from decel-
lularized tissue was seeded with TSC from rat patellar
tendons. This resulted in the production of tendon-like tissue
after 8 weeks, with highly organized collagen fibrils. Col-
lagen type I was extensively produced by these cells and
overall, the result was the formation of neo-tendon that was
comparable to that of healthy tissue.46 Similarly, the canine
decellularized tendon tissue matrix was seeded with BM-
MSC and tendon-derived stem cells (TDSCs). TDSC-seeded
DTT produced significantly more collagen type I after
14 days than TDSC alone. The DTT scaffolds were able to
produce tenogenic differentiation in both BM-MSCs and
TDSCs, as well as to control the alignment of these cells.100
BM-MSC seeded onto decellularized tendon matrix and
implanted in rabbit patellar tendon defects were able to
demonstrate the cells’ ability to proliferate and differentiate
toward a tendon-like phenotype in vivo, with increased gene
expression of tendon-related genes such as tenomodulin,
collagen type III, and MMPs.101
Conclusions
Treatment of tendon injuries and tendinopathies currently
remains a challenge, with repair often resulting in the pro-
duction of inferior tissue and long-term complications and
morbidity for patients. The need for a treatment strategy that
addresses the underlying pathophysiology of the damaged
tissue is evident. This article highlights the recent develop-
ments in the field of biomaterials science for the application
and delivery of regenerative factors for the repair of tendon
tissue. There is an unmet clinical need for an advanced ther-
apeutic that is able to recapitulate the spatiotemporal signal-
ing pathways seen in the healing process of tendon tissue. The
formulation of a therapeutic that is aimed at delivery of cells,
proteins, and genes in a suitable biomaterial carrier may prove
more successful than current singular approaches. The ideal
formulation will be easily delivered to the site of repair, will
degrade at a rate concomitant with de novo tissue formation,
and will be able to stimulate the body’s natural repair path-
ways, modulating cell proliferation and gene expression for
the synthesis of essential tendon components. Further inves-
tigation is required to determine the ideal biomaterial that will
be reproducible, scalable, nontoxic, nonimmunogenic, and
bioresobable, with the ability to deliver spatiotemporal cues
for the regeneration of tendon tissue. Current strategies based
around either injectable or implantable systems are proving
promising. Future exploration should be focused around the
discovery of the optimum combination of cells, proteins,
genes, and scaffolds that is able to orchestrate the complex
chain of events leading to a regenerated tissue mimicking the
native predamaged tendon, rather than the characteristic in-
ferior scar tissue currently associated with repair.
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